MORPHOSYS Stock Swiss Exchange
Equities
OXMOR
DE0006632003
Biotechnology & Medical Research
Sales 2024 * | 123M 133M | Sales 2025 * | 325M 354M | Capitalization | 2.56B 2.79B |
---|---|---|---|---|---|
Net income 2024 * | -430M -468M | Net income 2025 * | -116M -126M | EV / Sales 2024 * | 21.6 x |
Net Debt 2024 * | 89.28M 97.2M | Net cash position 2025 * | 94.69M 103M | EV / Sales 2025 * | 7.58 x |
P/E ratio 2024 * |
-6.02
x | P/E ratio 2025 * |
-32.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.39% |
Latest transcript on MORPHOSYS
Managers | Title | Age | Since |
---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 19-08-31 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 23-08-06 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 18-05-16 |
Director/Board Member | 67 | 18-05-16 | |
Marc Cluzel
CHM | Chairman | 69 | 12-05-30 |
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |